{"id":"obesity-pharmacotherapy","brandName":"Obesity pharmacotherapy","genericName":"Obesity pharmacotherapy","companyId":"denver-health-and-hospital-authority","companyName":"Denver Health and Hospital Authority","phase":"marketed","status":"active","modality":"Small molecule","aliases":["Phentermine or phentermine-topiramate (Qsymia)"],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Obesity pharmacotherapy represents a class of medications used to treat obesity and weight management, with Denver Health and Hospital Authority involved in clinical evaluation. The field encompasses multiple mechanistic approaches including GLP-1 receptor agonists (semaglutide), dual GIP/GLP-1 receptor agonists (tirzepatide), SGLT2 inhibitors (dapagliflozin), and investigational agents like nimacimab. Clinical development spans 50 trials across Phase 1–4 and observational studies, with active recruitment in post-smoking cessation weight management, binge eating disorder, and metabolic surgery optimization. The obesity pharmacotherapy market is experiencing rapid expansion driven by efficacy data and growing recognition of obesity as a chronic disease, with GLP-1 agonists achieving blockbuster status (semaglutide/Ozempic generating >$5B annually). Pipeline expansion includes combination therapies (tirzepatide + cognitive behavioral therapy), novel targets (brain plasticity modulation), and indication expansion into alcohol use disorder and endometrial cancer risk reduction.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a broad category encompassing multiple drug classes with different mechanisms, including GLP-1 receptor agonists (which slow gastric emptying and reduce hunger signals), lipase inhibitors (which reduce dietary fat absorption), and sympathomimetic amines (which increase energy expenditure). The specific mechanism depends on which agent is being used within the obesity pharmacotherapy portfolio.","oneSentence":"Obesity pharmacotherapy refers to a class of medications that reduce appetite, increase satiety, or enhance metabolic rate to promote weight loss.","_ai_confidence":"low"},"administration":{},"safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"trials":[],"indications":{"approved":[{"name":"Obesity management"},{"name":"Weight reduction in patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}